Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion type Assertion NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_head.
- NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion description "[These findings indicate that chronic intake of CNK-602A in a dose that does not affect plasma levels of T3 and T4 inhibits tonic convulsions in SER and suggest that this drug may be an effective treatment for convulsive seizures in patients with epilepsy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_provenance.
- NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion evidence source_evidence_literature NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_provenance.
- NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion SIO_000772 8603636 NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_provenance.
- NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion wasDerivedFrom befree-2016 NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_provenance.
- NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_assertion wasGeneratedBy ECO_0000203 NP1347571.RAXgt-MWKVZTMyrBn7SfUT_P8ZanrsxUGKYbEf6hjsP6E130_provenance.